Patents Assigned to Institut Pasteur
  • Publication number: 20220193198
    Abstract: The invention relates to Interleukin-2 (IL-2) variants for the prevention or treatment of immune disorders, including with no limitations allergic, autoimmune, chronic or acute inflammatory and infectious diseases; graft-versus-host disease; graft rejection and cancer. The invention also relates to the use of said IL-2 variants for the screening of anti-IL-2 antibodies with pro-T-effector or pro-T-regulatory cell activity.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 23, 2022
    Applicants: Institut Curie, Institut National de la Sante et de la Recherche Medicale, Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Eliane PIAGGIO, Sebastian AMIGORENA, Pamela CAUDANA, Felix REY, Gleyder ROMAN-SOSA, Pablo GUARDADO-CALVO
  • Patent number: 11364219
    Abstract: The present invention relates to the treatment of microbiome dysregulations. Said dysregulations may subsequently contribute to the development of several chronic diseases. Thus characterization of new post-biotic compounds inducing beneficial changes on host-microbiota interactions may be highly desirable. The inventors showed that Nlrp6 diurnally coordinates cyclical adaptation of the gut microbiota diversity to epithelial plasticity in response to a treatment with a Csnk2 inhibitor. The invention therefore relates to an inhibitor of Csnk2, for use in the treatment of microbiome dysregulations notably associated with circadian clock disruption. Said inhibitor may be selected among chemically synthesized or natural selective Csnk2 inhibitors such as flavones.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: June 21, 2022
    Assignees: INSERM (INSTITUT NATION DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE LILLE, INSTITUT PASTEUR DE LILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CRNS—
    Inventor: Mathias Chamaillard
  • Patent number: 11365264
    Abstract: Methods for diagnosing or treating immune disorders in a subject are provided. The methods are based on the detection or modulation of Refractory state Inducing Factor (RIF).
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: June 21, 2022
    Assignee: INSTITUT PASTEUR
    Inventors: Jacques Theze, Thierry Rose, Florence Bugault
  • Patent number: 11357831
    Abstract: The invention relates to the improvement of endonuclease-based antimicrobials by blocking DNA repair of double-strand break(s) (DSB(s)) in prokaryotic cells. In this respect, the invention especially concerns a method involving blocking DNA repair after a nucleic acid has been submitted to DSB, in particular by a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) associated programmable double-strand endonuclease. The invention particularly relates to the use of an exogenous molecule that inhibits DNA repair, preferably a protein that binds to the ends of the double-stranded break to block DSB repair. The invention also relates to vectors, particularly phagemids and plasmids, comprising nucleic acids encoding nucleases and Gam proteins, and a pharmaceutical composition and a product containing these vectors and their application.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: June 14, 2022
    Assignees: INSTITUT PASTEUR, ELIGO BIOSCIENCE
    Inventors: David Bikard, Lun Cui, Xavier Duportet, Jesus Fernandez Rodriguez
  • Patent number: 11351246
    Abstract: The invention relates a recombinant measles virus plasmid capable of expressing a human telomerase reverse transcriptase (hTERT) protein fused at N-terminus with a protein enhancing addressing of the hTERT protein to proteasome. The invention further relates to a vaccine comprising said plasmid or particles rescued therefrom, and uses thereof, especially in preventing or treating a tumor in a patient.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: June 7, 2022
    Assignees: INVECTYS SAS, INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Pierre Langlade Demoyen, Frédéric Tangy, Elodie Pliquet
  • Patent number: 11344515
    Abstract: The present invention relates to the field of muscle regeneration, and more particularly to the replenishment of the in vivo muscle stem cells pool. It more specifically relates to a 5-hydroxytryptamine B1 receptor-stimulating agent, and to a composition comprising said agent, for use as i) a promoter of satellite cells self-renewal and/or differentiation, and/or ii) an agent preventing and/or inhibiting the satellite cells pool exhaustion. The invention further encompasses therapeutic and screening methods.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: May 31, 2022
    Assignees: INSTITUT PASTEUR, UNIVERSITE PARIS DESCARTES, CENTRE HOSPITALIER SAINTE ANNE PARIS, INISTITI IT GI ISTAV/E Dm ICCV
    Inventors: Fabrice Bruno Chretien, Raphael Gaillard, Pierre Rocheteau, Olivier Mir
  • Patent number: 11339211
    Abstract: The invention is in the domain of delivery of molecules to brain cells across the blood-brain barrier. The invention relates to a novel polypeptide-based carrier that allows the efficient delivery of an effector peptide, to neuron cells across the blood-brain barrier, and to methods for the production and testing of such carrier, including a model for testing the capacity of such molecule to cross the blood-brain barrier and/or the toxicity of molecules on the blood brain barrier and/or the capacity of molecules that have crossed to target human brain cells (e/g. neurons, astrocytes and microglial cells).
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: May 24, 2022
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Christophe Prehaud, Monique Lafon, Pierre Lafaye
  • Publication number: 20220143060
    Abstract: The present disclosure relates to a method of preventing or treating an infectious disease in a subject, comprising the step of administering to the subject an antagonist or expression inhibitor for a natural killer (NK) cell immune checkpoint molecule. The present disclosure also relates to the use of an antagonist or expression inhibitor for an NK cell immune checkpoint molecular and pharmaceutical compositions comprising the same in the treatment of infectious diseases.
    Type: Application
    Filed: March 20, 2020
    Publication date: May 12, 2022
    Applicant: INSTITUT PASTEUR OF SHANGHAI, CHINESE ACADEMY OF SCIENCES
    Inventors: Hong TANG, Chao ZHANG, Hairong CHEN
  • Patent number: 11317848
    Abstract: The application generally relates to olfaction as a biomarker, more particularly as a prognostic biomarker or biological predictor, of neurosensory disease or disorder and/or of neurocognitive disease or disorder, in subjects whose nervous system has been infected by an infectious agent, such as by a neurotropic virus, bacterium, protozoan parasite, fungus or prion, more particularly by a neurotropic virus.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: May 3, 2022
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
    Inventors: Françoise Lazarini-Serandour, Pierre-Marie Lledo, Natacha Teissier, Sarah Levivien
  • Publication number: 20220128572
    Abstract: The invention relates to a method of predicting therapeutic responses to TNF blockers before anti-TNF therapy comprising analyzing immune parameters to selected stimuli in patients before therapy and its use for anti-TNF therapy. The invention relates also to a method of determining a predictive biomarker of response to anti-TNF therapy and to the use of the predictive biomarker obtained by the method.
    Type: Application
    Filed: January 3, 2022
    Publication date: April 28, 2022
    Applicants: INSTITUT PASTEUR, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, UNIVERSITE DE PARIS
    Inventors: LARS ROGGE, SILVIA MENEGATTI, MAXIME DOUGADOS, ELISABETTA BIANCHI
  • Publication number: 20220117960
    Abstract: The success of anti-tumor immune responses requires effector T cells to infiltrate solid tumors, a process guided by chemokines. Herein, we demonstrate that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4, also known as CD26) limits lymphocyte migration to sites of inflammation and tumors. Inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10, and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3. Furthermore, DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T cell transfer and checkpoint blockade. These findings provide the first direct in vivo evidence for controlling lymphocyte trafficking through CXCL10 cleavage and support the use of DPP4 inhibitors for stabilizing the biologically active form of chemokines as a strategy to enhance tumor immunotherapy.
    Type: Application
    Filed: December 15, 2021
    Publication date: April 21, 2022
    Applicants: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Rosa BARREIRA DA SILVA, Matthew ALBERT
  • Publication number: 20220119886
    Abstract: The application relates to means for diagnosing, predicting or monitoring Pneumocystis pneumonia (PCP). The means of the application are also suitable for determining or predicting the efficacy of a drug or treatment against PCP in a human patient. The means of involve the detection and/or quantification, more particularly the quantification, of the RNA transcripts of two different P. jirovecii mitochondrial genes. The first of said two P. jirovecii mitochondrial genes is the P. jirovecii gene, the sequence of which codes for the Cytb protein or the P. jirovecii mitochondrial Small Sub-Unit (mtSSU) gene. The second of said two P. jirovecii mitochondrial genes is a P. jirovecii gene, the sequence of which transcribes into a P. jirovecii ribosomal RNA, e.g., be the mitochondrial P. jirovecii Large Sub-Unit (mtLSU) gene.
    Type: Application
    Filed: December 15, 2021
    Publication date: April 21, 2022
    Applicants: INSTITUT PASTEUR, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, UNIVERSITE PARIS DIDEROT - PARIS 7
    Inventors: Alexandre ALANIO, Stephane BRETAGNE, Francoise DROMER, Aude STURNY-LECLERE, Benjamin HOMMEL, Marion BENAZRA
  • Patent number: 11305003
    Abstract: The present invention is directed to a Zika virus (ZIKV) chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition. The present invention provides means, in particular polynucleotides, vectors and cells expressing said chimeric polyepitope. The present invention also relates to a composition or a vaccine comprising at least one of said polyepitope, polynucleotide, vector or host cell for use in the prevention of a ZIKV infection in a human subject, or for use in the prevention of ZIKV and dengue vims (DENV) infections in a human subject.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: April 19, 2022
    Assignees: INSTITUT PASTEUR, UNIVERSIDAD EL BOSQUE
    Inventors: Claude Roth, Etienne Simon-Loriere, Anavaj Sakuntabhai, Felix Delgado
  • Publication number: 20220111040
    Abstract: Provided is a method for activating CD4+ T cells using a polymer-based antigen complex. The method comprises the steps of bringing the polymer-based antigen complex into contact with B cells so that B cells process and present the antigen complex, and of bringing the B cells into contact with CD4+ T cells to activate CD4+ T cells. Also provided are a method for promoting the differentiation of CD4+ T cells into Tfh cells and Thl cells using the antigen complex, and a method for treating diseases by activating CD4+ T cells and/or promoting the differentiation of CD4+ T cells.
    Type: Application
    Filed: August 6, 2019
    Publication date: April 14, 2022
    Applicants: INSTITUTE OF BIOPHYSCIS, CHINESE ACADEMY OF SCIENCES, INSTITUT PASTEUR OF SHANGHAI, CHINESE ACADEMY OF SCIENCES
    Inventors: Baidong HOU, Sheng HONG, Zhaolin HUA, Hong TANG
  • Patent number: 11287433
    Abstract: The invention relates to a method for in vitro investigating mitochondrial replication dysfunction in a biological sample removed from a subject susceptible of suffering from physiological ageing or physiopathological conditions related to physiological ageing, or physiopathological ageing or associated symptoms or conditions, in particular premature ageing or accelerated ageing, or of a progeroid syndrome, such as Cockayne syndrome (CS), or neurodegenerative disorders or symptoms thereof, in which the levels of at least one species selected in the group of: POLG1 protein, POLG1 RNA, POLG2 protein, protease(s) which have POLG as a target, in particular serine protease(s) such as HTRA3 protein, HTRA2 protein and, HTRA3 RNA or HTRA2 RNA, or any combination of these species, are investigated.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: March 29, 2022
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, COMMISSARIAT A L'ENERGIE ATOMIOUE ET AUX ENERGIES ALTERNATIVES
    Inventors: Laurent Arnaud Chatre, Miria Ricchetti, Alain Sarasin, Denis Biard
  • Patent number: 11279714
    Abstract: The present invention relates to small molecule compounds having the general formula (I): wherein A is a moiety selected from the group consisting of formulae (A) to (K) and their use in the treatment of bacterial infections, in particular Tuberculosis.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: March 22, 2022
    Assignee: INSTITUT PASTEUR KOREA
    Inventors: Jaeseung Kim, Sunhee Kang, Juhee Kang, Sumi Lee, Jeong Jea Seo, Mooyoung Seo
  • Patent number: 11246858
    Abstract: Within the scope of the present invention is a new pharmacological strategy for the treatment of tumors based on anti-tumoral immune responses.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: February 15, 2022
    Assignee: INSTITUT PASTEUR DE MONTEVIDEO
    Inventors: Marcelo Hill, Mercedes Segovia, Sofia Russo, Mathias Jeldres, Maria Romina Girotti, Maite Duhalde Vega, Yamil Damián Mahmoud
  • Patent number: 11249090
    Abstract: The invention relates to a method of predicting therapeutic responses to TNF blockers before anti-TNF therapy comprising analyzing immune parameters to selected stimuli in patients before therapy and its use for anti-TNF therapy. The invention relates also to a method of determining a predictive biomarker of response to anti-TNF therapy and to the use of the predictive biomarker obtained by the method.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: February 15, 2022
    Assignees: INSTITUT PASTEUR, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, UNIVERSITE DE PARIS
    Inventors: Lars Rogge, Silvia Menegatti, Maxime Dougados, Elisabetta Bianchi
  • Publication number: 20220042987
    Abstract: The invention relates to the diagnosis of a SARS-associated coronavirus, such as a SARS CoV-2 infection and SARS-CoV infection, using the SARS-CoV and SARS-CoV-2 nucleocapsid proteins and antibodies binding to these proteins. The invention encompasses reagents, methods and kits for the detection of a SARS-associated coronavirus.
    Type: Application
    Filed: February 3, 2021
    Publication date: February 10, 2022
    Applicant: INSTITUT PASTEUR
    Inventors: Sylvie VAN DER WERF, Nicolas ESCRIOU, Caroline DEMERET, Stéphane PETRES, Pierre LAFAYE, Jacques BELLALOU
  • Patent number: 11236390
    Abstract: The application relates to means for diagnosing, predicting or monitoring Pneumocystis pneumonia (PCP). The means of the application are also suitable for determining or predicting the efficacy of a drug or treatment against PCP in a human patient. The means of involve the detection and/or quantification, more particularly the quantification, of the RNA transcripts of two different P. jirovecii mitochondrial genes. The first of said two P. jirovecii mitochondrial genes is the P. jirovecii gene, the sequence of which codes for the Cytb protein or the P. jirovecii mitochondrial Small Sub-Unit (mtSSU) gene. The second of said two P. jirovecii mitochondrial genes is a P. jirovecii gene, the sequence of which transcribes into a P. jirovecii ribosomal RNA, e.g., be the mitochondrial P. jirovecii Large Sub-Unit (mtLSU) gene.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: February 1, 2022
    Assignees: INSTITUT PASTEUR, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, UNIVERSITE PARIS DIDEROT—PARIS 7
    Inventors: Alexandre Alanio, Stéphane Bretagne, Françoise Dromer, Aude Sturny-Leclere, Benjamin Hommel, Marion Benazra